NCCN 2016 Congress Webinar Series: Breast Cancer - Early Stage Breast Cancer: Role of Multigene Assays & SABCS Updates on Adjuvant & Neoadjuvant Therapies

April 8, 2016

Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The clinical evaluation and therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied.  Healthcare professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions, to communicate treatment options to patients effectively in order to make shared treatment decisions, and to provide optimal care for patients with breast cancer.

As the complexity and importance of screening, testing, and individualized treatment strategies for breast cancer have increased, so has clinicians’ reliance on the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines and NCCN’s educational interventions to increase knowledge and bridge the gaps between knowledge and competence.
This webinar series will provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines for Breast Cancer, to ensure that oncologists and other oncology healthcare professionals have a clear understanding of breast cancer diagnosis, staging and initial therapy, radiation therapy in the management of locoregional disease, adjuvant therapy for locoregional disease, and metastatic disease management.

This webinar will feature updates on information presented at the 2015 San Antonio Breast Cancer Symposium (SABCS).

Target Audience

This educational program is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with breast cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Select appropriate clinical tools to estimate risk of relapse and the benefits of adjuvant systemic therapy.
  • Discuss emerging data and recent advances in the treatment of patients with breast cancer and integrate key findings into clinical practice.
  • Identify emerging agents with novel mechanisms of action and, as appropriate, incorporate these into treatment strategies to optimize patient outcomes.
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Celgene Corporation
  • Genentech
  • Genomic Health, Inc.
  • Lilly
  • Novartis Oncology
  • Pfizer
Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
Course expires: 
Event starts: 
04/08/2016 - 2:30pm EDT
Event ends: 
04/08/2016 - 3:30pm EDT

Matthew Goetz, MD
Mayo Clinic Cancer Center

Sarika Jain, MD, MSCI
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Cesar A. Santa-Maria, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University


Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.


National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-021-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing